Rachel Mikhael

Accountable for shaping the CDx ecosystem across Lebanon and Jordan, enabling diagnostic readiness aligned with
oncology launch priorities through strategic partnerships with laboratories and stakeholders. Oversaw commercial
frameworks, PD-L1 testing quality, pathology capability development, and approvals of patient support programs.
• Supervise and develop one marketing assignee supporting CDx across Lebanon and Jordan.
• Lead the Lebanon and Jordan kit provision program, ensuring operational continuity and supply availability.
• Direct the 22C3 testing network across partner laboratories to maintain diagnostic readiness.
• Collaborate with medical colleagues to facilitate pathology capability building, linking local laboratories with
Agilent Dako global training.
• Manage commercial and operational agreements with local laboratories and distributors.
• Oversee order processing, including purchase orders, invoicing, and distributor coordination.
• Conduct annual capability-building sessions for product specialists on emerging CDx trends and best practices.

Accountable for leading oncology brand and indication portfolio strategy across Lebanon and Jordan, driving prioritization and resource allocation while overseeing commercial planning and investments and partnering with regional and cross-functional teams to accelerate launches, market growth, and patient access across Levant markets.
• Develop and execute the annual strategic marketing plan, defining brand strategy and implementation roadmap.
• Identify growth opportunities across immuno-oncology indications and shape portfolio strategy accordingly.
• Lead new product launch planning, defining where to play, how to win, and execution priorities.
• Partner with regional and global marketing, medical, market access, pricing, and supply teams to align brand priorities.
• Develop KOL engagement strategies in collaboration with the medical team to strengthen scientific leadership.
• Manage promotional investments and contribute to business planning and P&L management for Levant markets.
• Lead disease awareness initiatives in collaboration with Ministries of Health and medical societies.
• Support policy shaping and patient access strategies in collaboration with market access teams.
Key Achievements:
• Drove Keytruda to market leadership in Jordan, achieving 75 to 80% market share and establishing it as the #1 oncology and IO therapy.
• Contributed to positioning Keytruda in Lebanon as the #1 pharmaceutical product, #1 oncology product, and leading IO therapy, reaching about 70% market share.
• Led the successful launch of Welireg in Lebanon, ensuring cross-functional readiness and market introduction of the first-in-class HIF-2α inhibitor for renal cell carcinoma.

Led the EEMEA commercialization strategy for Endometrial Cancer, driving launch readiness and cross-market alignment across multiple countries and functions.
Partnered with regional and global stakeholders to shape go-to-market strategy and performance tracking across diverse market archetypes.
• Led the development and execution of the EEMEA commercialization plan for Endometrial Cancer.
• Partnered with cross-functional stakeholders to shape go-to-market strategies and tactics for early and first-line metastatic Endometrial Cancer.
• Drove insight generation, KPI development, and performance tracking to inform strategic decisions.
• Ensured regional readiness of global marketing materials, messaging, and stakeholder capability-building initiatives.
• Supported development and execution of medical education, training and coaching of key stakeholders.
Key Achievements:
• Co-developed the global brand plan for Endometrial Cancer, driving launch readiness and regional adaptation across EEMEA markets in partnership with country brand leaders.
• Led collaboration with country brand teams across EEMEA to strengthen forecasting for Women’s Cancer indications, enabling more robust regional planning and data-driven portfolio decisions.
• Drove alignment of regional markets with the global Women’s Cancers strategy, reinforcing portfolio positioning and ensuring strategic consistency across EEMEA.

Accountable for shaping the Womens Cancers narrative and leading the regional omnichannel strategy across multiple EEMEA markets, partnering with regional teams and country brand managers to drive strategic alignment, consistent positioning, and performance optimization.
• Shaped the Women’s Cancers narrative across markets to ensure consistent portfolio positioning among key stakeholders.
• Championed the regional omnichannel agenda through adoption of the Global Omnichannel Framework and Launch Model.
• Partnered with GBS/DMCE to localize omnichannel campaigns and support execution across indications and markets.
• Served as the regional liaison for localization, performance tracking, and issue resolution in collaboration with DMCE.
• Drove alignment on the global tagging taxonomy to strengthen campaign measurement and reporting.
• Coordinated marketing capability-building initiatives across the region.
Key Achievements:
• Delivered the successful rollout of TNBC omnichannel campaigns across multiple EEMEA markets, with several
countries achieving top rankings on the global performance dashboard.